Notification about latest news from us.
Novo Nordisk lowers prices for Wegovy and Ozempic to $349 and introduces a $199 introductory rate, enhancing market competition in obesity treatments.
Pfizer secures a $10 billion acquisition of Metsera, concluding a heated bidding war against Novo Nordisk.
Novo Nordisk announces plans to cut 9,000 jobs amid rising competition and profit warnings in the obesity drug market, focusing resources on growth sectors.
By clicking send you'll receive occasional emails from newsletters about this topic.